616 related articles for article (PubMed ID: 22711607)
21. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
22. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
24. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
26. Cooperative p16 and p21 action protects female astrocytes from transformation.
Kfoury N; Sun T; Yu K; Rockwell N; Tinkum KL; Qi Z; Warrington NM; McDonald P; Roy A; Weir SJ; Mohila CA; Deneen B; Rubin JB
Acta Neuropathol Commun; 2018 Feb; 6(1):12. PubMed ID: 29458417
[TBL] [Abstract][Full Text] [Related]
27. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
28. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
29. Effect of extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on delaying aging of vascular smooth muscle cells in aged rats.
Tao LL; Lei Y; Wang GL; Zhu LQ; Wang Y
Chin J Integr Med; 2012 Aug; 18(8):582-90. PubMed ID: 22855034
[TBL] [Abstract][Full Text] [Related]
30. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
31. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
33. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
34. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.
Li P; Zhang X; Gu L; Zhou J; Deng D
PLoS One; 2019; 14(10):e0223084. PubMed ID: 31652270
[TBL] [Abstract][Full Text] [Related]
35. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
36. Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Nonomura Y; Nagasaka K; Hagiyama H; Sekine C; Nanki T; Tamamori-Adachi M; Miyasaka N; Kohsaka H
Arthritis Rheum; 2006 Jul; 54(7):2074-83. PubMed ID: 16802342
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
38. Preimplantation-embryo-specific cell-cycle regulation is attributable to a low expression of retinoblastoma protein rather than its phosphorylation.
Egashira A; Kano K; Naito K
J Reprod Dev; 2011 Sep; 57(4):492-9. PubMed ID: 21519154
[TBL] [Abstract][Full Text] [Related]
39. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
40. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]